Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese population.
Authors: Joshi N,  Johnson LL,  Wei WQ,  Abnet CC,  Dong ZW,  Taylor PR,  Limburg PJ,  Dawsey SM,  Hawk ET,  Qiao YL,  Kirsch IR
Journal: Cancer Epidemiol Biomarkers Prev
Date: 2006 May
Branches: MEB, GEB
PubMed ID: 16702392
PMC ID: not available
Abstract: Selenium is a promising cancer chemoprevention agent. A recent randomized controlled chemoprevention trial found that selenomethionine (SeMet) supplementation for 10 months favorably effected a change in esophageal dysplasia grade among participants who started the trial with mild dysplasia. To further explore the role of SeMet in this trial, we compared gene expression profiles by treatment group using Affymetrix HU 133A chips in before/after supplementation paired normal esophageal biopsies from a subset of 29 trial participants, 16 who received SeMet, and 13 who received placebo. Using P < 0.001 as a cutoff, 11 differentially expressed genes were found in the SeMet supplementation group but these genes did not include either known selenoprotein genes or genes previously shown to be modulated by selenium treatment. Because the number of differentially expressed genes (n = 11) was less than expected by chance (n = 18), we concluded that SeMet supplementation had no measurable effect on gene expression in the normal squamous esophagus of these subjects with dysplasia.